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Background: Currently, there are no direct comparisons of apixaban and rivaroxaban, two new 
oral direct factor Xa inhibitors approved for management of thromboembolic disorders.
Objective: Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban 
and rivaroxaban.
Methods: In this randomized, open-label, two-period, two-treatment crossover study, healthy 
subjects (N=14) received apixaban 2.5 mg twice daily (BID) and rivaroxaban 10 mg once daily 
(QD) for 4 days with a $4.5-day washout. Plasma samples were obtained for pharmacokinetic 
and AXA assessments; parameters were calculated using noncompartmental methods.
Results: Median time-to-maximum concentration was 2 hours for both compounds, and the 
mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively. Daily exposure, 
the area under the curve (AUC(0–24)), appeared similar for rivaroxaban (1,094 ng ⋅ h/mL) and 
apixaban (935 ng ⋅ h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold 
greater for rivaroxaban (16.9) than apixaban (4.7). Coefficient of variation for exposure param-
eters (AUC0–24, Cmax, Cmin) was 20%–24% for apixaban versus 29%–46% for rivaroxaban. Peak 
AXA, AXA AUC(0–24), and AXA fluctuation were ~2.5-, 1.3-, and 3.5-fold higher for rivaroxaban 
than apixaban, respectively. Trough concentrations and AXA were lower for rivaroxaban (10 
ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively). Rivaroxaban 
exhibited a steeper concentration–AXA response (slope: 0.0172 IU/ng vs 0.0134 IU/ng for 
apixaban, P,0.0001).
Conclusion: Apixaban 2.5 mg BID demonstrated less intersubject variability in exposure, lower 
AXA AUC, and higher trough and smaller peak-to-trough fluctuations in plasma concentration 
and AXA, suggesting more constant anticoagulation compared with rivaroxaban 10 mg QD. 
However, the clinical impact of these differences on the relative efficacy and safety of apixaban 
and rivaroxaban remains to be determined.
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Introduction
Apixaban and rivaroxaban are oral direct reversible factor Xa (FXa) inhibitors approved 
for the prevention of several thromboembolic disorders. Based on the current litera-
ture, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of these two FXa 
inhibitors share some general features.1,2 The bioavailability of apixaban is ~50% and 
is not significantly influenced by dose or administration with meals.3 Rivaroxaban 
bioavailability ranges from 66%–100%, depending on the dose and whether or not 
the dose is administered with a meal. Rivaroxaban requires administration with food 
to achieve similar bioavailability between a 10 mg dose and doses $15 mg.4 Both 
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Dovepress 
Dovepress
180
Frost et al
after administration. Protein binding is similar for the two 
compounds (apixaban ∼87%, rivaroxaban ∼93%). Apixaban 
and rivaroxaban also share similar pathways of elimination 
including metabolism, mainly by cytochrome P450 3A4 
(CYP3A4), as well as biliary and renal elimination, and have 
relatively similar terminal half-lives (apixaban ∼12 hours, 
rivaroxaban ∼10 hours). Despite these similar PK proper-
ties, these agents are administered differently. Rivaroxaban 
is administered once daily (QD), twice daily (BID), or a 
combination of QD and BID, depending on the indication, 
whereas apixaban is administered BID for all indications. 
Although individual literature reports are helpful to form a 
general understanding of their relative PK and PD profiles, 
no direct comparisons of these agents have been performed 
in humans. Such a comparison could help elucidate how 
their PK and PD properties, along with their posology, 
relate to observed clinical outcomes, and may aid in the 
transition between therapies. The purpose of this study was 
to compare the PK and PD (anti-factor Xa activity [AXA]) 
profiles of apixaban (2.5 mg BID) and rivaroxaban (10 mg 
QD) in healthy subjects at the doses and schedules approved 
for prevention of venous thromboembolism (VTE) following 
elective knee or hip replacement surgery.5,6
Methods
study design
This study (EudraCT 2009-017278-19) was a randomized, 
open-label, two-period, two-treatment crossover study in 
14 healthy subjects. Primary objectives were to assess the 
multiple-dose, steady-state PK profiles and compare plasma 
concentration peak-to-trough ratios (Cmax/Cmin) of rivaroxaban 
10 mg QD with those of apixaban 2.5 mg BID following 
oral administration in healthy subjects.   Secondary objec-
tives included assessment of the multiple-dose, steady-state 
AXA profiles and safety and tolerability of these agents. The 
study was carried out in compliance with the International 
Conference on Harmonisation guidelines for Good Clinical 
Practice and in accordance with the principles of the 
Declaration of Helsinki, including all amendments in effect 
up to the time the study was conducted. Study protocol and 
informed consent forms were reviewed and approved by 
an independent ethical committee (Stichting Beoordeling 
Biomedisch Ethiek Onderzoek, Assen, the Netherlands), 
and all parts of the study were in compliance with the EU 
Clinical Trial Directive (EU CTD) 2001/20/EC.
Screening was carried out within 21 days prior to study 
drug administration and all subjects provided written informed 
consent prior to the start of any study-related procedures.
Eligible subjects were admitted to the clinical facility 
(PRA International, Zuidlaren, the Netherlands) the day 
before the first treatment period and remained in the clinical 
facility for the duration of the study. Subjects were random-
ized 1:1, according to a computer-generated randomization 
scheme, to receive either apixaban 2.5 mg BID (every 
12 hours) or rivaroxaban 10 mg QD (every 24 hours) for 
4 days followed by a $4.5-day washout before receiving 
the alternate treatment (Figure 1). Four days of dosing was 
selected to ensure that both agents achieved steady state; 
apixaban achieves steady state within 2–3 days of adminis-
tration with modest accumulation (,2-fold) following BID 
dosing, and rivaroxaban does not show appreciable accumula-
tion following QD administration.7,8
inclusion and exclusion criteria
Eligibility criteria included age 18–45 years, body mass 
index of 18–30 kg ⋅ m-2, inclusive, and a healthy condition 
according to physical examination, vital sign assessment, 
clinical laboratory assessment, and medical history. Reasons 
for exclusion from the study included any significant or acute 
medical illness or relevant trauma; gastrointestinal disease 
or surgery in the previous 3 months; a history of abnormal 
bleeding or coagulation disorder; any significant head injury 
within the previous 2 years; any major surgery within 4 weeks 
prior to dosing or planned within 2 weeks after completion 
S R
Rivaroxaban 10 mg QD
×4 days
Rivaroxaban 10 mg QD
×4 days
N=14
W
D
7 4 1 1 Day –21 4
Apixaban 2.5 mg BID
Q12 hours ×4 days
Apixaban 2.5 mg BID
Q12 hours ×4 days
Period 1 Period 2
Figure 1 study design schematic.
Abbreviations: BiD, twice daily; D, discharge; Q12 hours, every 12 hours; QD, once daily; r, randomization; s, screening; W, washout (#4.5 days).Clinical Pharmacology: Advances and Applications 2014:6 submit your manuscript | www.dovepress.com
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of the study; or any history of acute or chronic pancreatitis. 
Female subjects were excluded if pregnant or breastfeeding 
and were required to have a negative serum or urine preg-
nancy test within 24 hours prior to dosing. All subjects were 
required to use an acceptable method of contraception for 
the duration of the study. Subjects were also excluded for a 
recent history of smoking or alcohol abuse.
Assessments
Blood sampling
Blood samples (4 mL) for measurement of rivaroxaban 
plasma concentrations were collected in potassium EDTA 
tubes predose on days 1 and 4 of the treatment period and 
at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 20, 
24, 36, 48, and 72 hours after the morning dose on day 
4 of the treatment period. Blood samples (2.7 mL) for 
measurement of apixaban plasma concentrations were 
collected in 3.2% sodium citrate tubes predose on days 
1 and 4 of each treatment period and at 0.5, 1, 2, 3, 4, 5, 
6, and 8 hours after the morning dose, and at predose (12 
hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 60 hours 
after the evening dose on day 4 of the treatment period. 
Samples were stored on ice immediately after collection 
and processed within 30 minutes by centrifugation for 15 
minutes at 1,500× g, 4°C. Plasma from each sample was 
then transferred to a separate vial and stored at #-20°C 
until shipped on dry ice for analysis.
Apixaban and rivaroxaban samples were assayed by vali-
dated liquid chromatography–mass spectrometry/mass spec-
trometry (LC–MS/MS) methods at Intertek Pharmaceutical 
Services (formerly known as Alta Analytical Laboratory, 
El Dorado Hills, CA, USA) and at PPD Inc. (Middleton, 
WI, USA), respectively. For apixaban, sample extraction 
for plasma utilized protein precipitation. Apixaban-M4 
(a hydroxylated metabolite of apixaban) was used as the 
internal standard for the assay. The lower limit of quantifica-
tion (LLOQ) for apixaban was 1.00 ng/mL. The between-run 
and within-run variability (coefficient of variation [CV]) for 
apixaban in quality control samples were #6.7% and #4.1%, 
respectively, with deviations from the nominal concentration 
of no more than ±3.7%. All samples were analyzed within the 
period of analyte stability. For rivaroxaban, sample extraction 
for plasma utilized liquid–liquid extraction. Rivaroxaban-d4 
(deuterium-radiolabeled rivaroxaban) was used as the internal 
standard for the assay. The LLOQ for rivaroxaban was 0.5 
ng/mL. The between-run and within-run variability (CV) 
for rivaroxaban in quality control samples were #5.1% 
and #8.8%, respectively, with deviations from the nominal 
concentration of no more than ±5.6%. All samples were 
analyzed within the period of analyte stability.
Pharmacokinetics 
PK parameters for apixaban and rivaroxaban were derived 
from the plasma concentration–time data on day 4 and 
included maximum observed plasma concentration within the 
dosing interval (Cmax), minimum observed plasma concentra-
tion within the dosing interval (Cmin), time of Cmax (Tmax), and 
area under the plasma concentration–time curve within the 
dosing interval (AUC(0–12) and AUC(0–24), respectively). Apixa-
ban daily AUC (AUC(0–24)) was calculated as the sum of the 
AUC(0–12) and AUC(12–24) observed following administration of 
the morning and evening dose, respectively. Terminal half-life 
(T1/2) was calculated following the last dose (ie, following 
the day 4 evening dose for apixaban and following the day 4 
morning dose for rivaroxaban). Plasma concentration peak-
to-trough ratios (Cmax/Cmin) were calculated.
Anti-factor Xa activity
Blood samples (2.7 mL) for the determination of AXA for 
both drugs were collected in 3.2% sodium citrate tubes at 
the same time points as the PK samples, and kept at room 
temperature for no more than 30 minutes before centrifug-
ing at 18°C and 1,500× g for 15 minutes. Plasma was col-
lected from each sample and stored in cryovials at #-70°C. 
Samples were shipped on dry ice to Esoterix Coagulation 
Laboratory (Englewood, CO, USA) for analysis of AXA 
using a validated chromogenic anti-FXa assay (Rotachrom®; 
Diagnostica Stago Inc., Parsippany, NJ, USA)9 with a report-
able range of 0.10 IU/mL to 18.5 IU/mL for apixaban and 
rivaroxaban.9,10
AXA parameters for both compounds were derived from 
plasma AXA time data obtained on day 4 over the dosing inter-
val as described above for PK. Parameters assessed included 
peak and trough plasma AXA, time to peak AXA (Tpeak), area 
under the plasma AXA–time curve, and AXA half-life.
safety
Physical examination, measurement of vital signs, 12-lead 
electrocardiogram (ECG), and blood/urine clinical laboratory 
testing were performed at screening, prior to each treatment 
period, and at study discharge, with close monitoring for 
adverse events (AEs) throughout the study. All AEs were 
coded by the investigator using the Medical Dictionary for 
Regulatory Activities (MedDRA; v12.1) and recorded along 
with severity, timing of onset, relationship to study drug, 
and outcome.Clinical Pharmacology: Advances and Applications 2014:6 submit your manuscript | www.dovepress.com
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statistical methods
Data from 12 subjects were expected to provide $90% prob-
ability that the lower limit of the 90% confidence interval (CI) 
for the geometric mean ratio of Cmax/Cmin values (rivaroxaban/
apixaban) would be .1. An additional two subjects were 
enrolled to allow for early withdrawals. This estimate was 
based on the assumptions that the expected Cmax/Cmin ratio 
was $30% greater for rivaroxaban than apixaban,11,12 Cmax/
Cmin would be log-normally distributed, and intersubject 
standard deviation would not be greater than 0.22.13
Mean and individual steady-state concentration–time 
and AXA–time profiles were plotted for both apixaban and 
rivaroxaban. Scatter plots of AXA versus plasma concentra-
tion were plotted for both compounds and analyzed by linear 
regression. Individual PK and PD parameters were estimated 
using noncompartmental methods with WinNonlin® Professional 
(v5.0.1; Pharsight Corporation, Sunnyvale, CA, USA). Terminal 
elimination rate constants were estimated using the WinNonlin 
algorithm and AUC parameters were calculated using the log-
linear trapezoidal rule (WinNonlin Method 1). Actual sampling 
times were used for all parameter calculations. Descriptive 
statistics for PK and PD parameters were tabulated.
Results
Demographics and disposition
The study was conducted between February and March 2010. 
A total of 14 healthy subjects (eleven male, three female) 
were enrolled and received study medication. All 14 subjects 
completed the study. A summary of subject demographics 
is shown in Table 1.
Pharmacokinetics
Mean and individual plasma concentration–time profiles 
from day 4 of treatment for both compounds are shown in 
Figure 2, and summary statistics of the PK data are provided 
in Table 2. Median time to peak plasma concentration (Tmax) 
was 2 hours for both compounds. Peak concentrations were 
followed by a multiphasic decline with a mean terminal half-
life of 8.7 hours for apixaban versus 7.9 hours for rivaroxaban. 
Evaluation of mean trough concentrations on days 4 and 5 
indicated that steady state for both apixaban and rivaroxaban 
had been reached by the fourth day of dosing. On day 4, 
rivaroxaban Cmax was 171 ng/mL, ~2-fold higher than for 
apixaban (81 ng/mL). Conversely, the Cmin for rivaroxaban 
(10 ng/mL) was ~40% lower than for apixaban (17 ng/mL). 
The greater fluctuation in rivaroxaban plasma concentration 
over the dosing interval was reflected in the differences in the 
Cmax/Cmin ratio. The geometric mean of the Cmax/Cmin ratio for 
rivaroxaban (16.9) was 3.6-fold higher (90% CI: 2.82–4.61) 
than that for apixaban (4.7). Despite the difference in Cmax/
Cmin ratio over the dosing interval, the daily AUC at steady 
state (AUC0–24) was only ∼17% higher for rivaroxaban 
(mean [%CV] AUC(0–24): rivaroxaban =1,094 [29] ng ⋅ h/mL; 
apixaban =935 [24] ng ⋅ h/mL). Intersubject variability, 
expressed as %CV , was lower for apixaban exposure param-
eters (20%–24%) than for rivaroxaban exposure parameters 
(29%–46%).
Pharmacodynamics
The results of the PD analyses were similar to those of the 
PK analyses for apixaban and rivaroxaban. Plots of mean 
and individual AXA over time are shown in Figure 3, and 
summary statistics of the PD data are provided in Table 3. A 
close temporal relationship between plasma concentration 
and AXA was seen for both compounds across the dosing 
interval (compare Figures 2 and 3). Plotting AXA against 
plasma concentration of each drug (Figure 4) confirmed 
a direct linear relationship for both compounds; the slope 
of the regression lines appeared to be different (slope: 
  rivaroxaban 0.0172 IU/ng vs apixaban 0.0134 IU/ng; 
P,0.0001). Consistent with the PK findings, AXA fluc-
tuated less over the dosing interval for apixaban than for 
rivaroxaban. The geometric mean peak-to-trough AXA 
ratio for rivaroxaban was 3.5-fold higher than for apixaban 
(16.5 vs 4.7, respectively): peak AXA was ~2.5-fold higher 
for rivaroxaban than for apixaban (2.82 IU/mL [%CV 51] vs 
1.12 IU/mL [%CV 21]), whereas trough AXA was ~30% 
lower for rivaroxaban than for apixaban (Table 3). The AXA 
geometric mean AUC(0–24) was ~34% higher for rivaroxaban 
than for apixaban (17.8 IU ⋅ h/mL vs 13.3 IU ⋅ h/mL). 
Table 1 Population demographics
N=14
sex, n (%)
    Male  
Female
11 (79)  
3 (21)
race, n (%)
  White 12 (86)
  Multiple (Black and White) 2 (14)
Age, years
    Mean (sD)  
range
29 (9.1)  
20–43
height, cm
    Mean (sD)  
range
181 (7.4)  
170–195
Weight, kg
    Mean (sD)  
range
75.9 (10.2)   
62.9–94.4
BMi, kg ⋅ m-2
    Mean (sD)  
range
23.1 (2.5)  
19.4–28.1
Abbreviations: BMi, body mass index; n, total number of subjects; sD, standard 
deviation.Clinical Pharmacology: Advances and Applications 2014:6 submit your manuscript | www.dovepress.com
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Apixaban mean AXA half-life (8.9 hours) was similar to 
the half-life observed for plasma concentration (8.7 hours). 
Rivaroxaban mean AXA half-life could not be estimated 
over a similar time interval as for plasma concentration since 
AXA results for all but two subjects were below the assay’s 
LLOQ 24 hours after administration.
safety
Apixaban and rivaroxaban were well-tolerated in this study. 
A total of 22 AEs were reported by ten subjects after the start 
of study medication. Twelve AEs were reported by seven 
subjects following rivaroxaban administration, consisting of 
contusion, pharyngitis, and rhinitis, each reported twice, and 
single reports of epistaxis, abdominal discomfort, abdomi-
nal distension, diarrhea, paresthesia, and procedural pain. 
Ten AEs were reported by eight subjects following adminis-
tration of apixaban, consisting of three reports of dizziness, 
two reports of contusion, and single reports of epistaxis, 
catheter site hematoma, catheter site-related reaction, cough, 
and musculoskeletal chest pain. All AEs reported during the 
study were mild and resolved without treatment. No deaths 
or serious AEs were reported for either compound during 
the study, and no subjects discontinued treatment because of 
AEs or for other reasons. There were no findings of clinical 
relevance with respect to clinical laboratory tests, vital signs, 
ECGs, or physical examinations.
Discussion
This study provides the first head-to-head comparison of 
the PK and PD profiles for apixaban administered BID and 
Table 2 summary statistics: steady-state pharmacokinetics of rivaroxaban and apixaban
N=14 Cmax (ng/mL)  
G mean  
(%CV)
Cmin (ng/mL)  
G mean  
(%CV)
Cmax:Cmin  
G mean 
(%CV)
Tmax (h)  
median 
(min–max)
AUC(0–12) (ng ⋅ h/mL)  
G mean (%CV)
AUC(0–24) (ng ⋅ h/mL)  
G mean (%CV)
T1/2 (h) 
Mean (SD)
rivaroxaban  
10 mg QD
171 (46) 10.1 (39) 16.9 (53.5) 2.00 (1.0–3.0) 1,094 (29) 7.89 (3.00)
Apixaban  
2.5 mg BiD
80.5 (23) 17.1 (20) 4.7 (16.9) 2.00 (1.0–3.0) 527 (22) 935 (24) 8.65 (2.19)*
Note: *Determined after administration of evening dose.
Abbreviations: AUC(0–12), area under plasma concentration–time curve from time 0 to 12 hours after morning dose; AUC(0–24), area under plasma concentration–time curve 
from time 0 to 24 hours after morning dose; BiD, twice daily; Cmax, maximum observed plasma concentration; Cmin, minimum observed plasma concentration; CV, coefficient of 
variation; g mean, geometric mean; min, minimum; max, maximum; n, total number of subjects; QD, once daily; sD, standard deviation; T1/2, terminal half-life; Tmax, observed 
time of Cmax.
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rivaroxaban administered QD. Both apixaban 2.5 mg BID 
and rivaroxaban 10 mg QD were readily absorbed, reaching 
Tmax in 2 hours, and both agents had multiphasic elimination 
profiles with terminal half-lives of ~8 hours. For apixaban 
2.5 mg BID, there is significantly less daily fluctuation in 
plasma concentrations and AXA (ie, lower peak-to-trough 
ratio), as well as less variability in PK parameters (ie, Cmax 
and AUC), than for rivaroxaban 10 mg QD. The PK results for 
apixaban in this study were generally consistent with previ-
ously published multiple-dose data on apixaban7,14 in healthy 
subjects. The fluctuations in mean apixaban concentrations 
following administration of apixaban 2.5 mg BID in multiple 
ascending dose studies in Western and Japanese subject 
populations were ∼3.0 and ∼4.2, respectively, and the mean 
terminal half-lives were 8.1 and 9.7 hours, respectively.7,14 To 
our knowledge, the multiple-dose steady-state PK of rivar-
oxaban 10 mg QD in healthy subjects have not previously 
been reported, and the limited available data for 5 mg QD8 
do not permit estimation of the concentration fluctuation, 
although the half-life (8.4 hours) was similar to that in the 
current study.
Although the PK and PD profiles of rivaroxaban and apixa-
ban in VTEp patients differ somewhat from that in healthy 
subjects due to differences in covariates impacting the PK, the 
observations in healthy subjects are generally relevant to the 
patient population. Specifically, for rivaroxaban, it appears that 
Table 3 summary statistics: steady state anti-FXa activity of rivaroxaban and apixaban
N=14 Peak (IU/mL)  
G mean (CV)
Trough (IU/mL)  
G mean (CV)
Peak:trough  
G mean  
(CV)
Tpeak (h)  
median  
(min–max)
AUC(0–12)  
(IU ⋅ h/mL)  
G mean (CV)
AUC(0–24)  
(IU ⋅ h/mL)  
G mean (CV)
T1/2 (h) 
Mean 
(SD)
rivaroxaban 10 mg  
QD (0–24 h)
2.82 (51) 0.170* (32) 16.5* (57.4) 2.00 (1.00–3.00) 17.8 (29) ne#
Apixaban 2.5 mg  
BiD (0–12 h)
1.12 (21) 0.240 (22) 4.7 (19.5) 2.00 (1.00–3.00) 7.42 (21) 13.3 (22) 8.91 (2.46)‡
Notes: Anti-FXa activity is expressed in lMWh units; *n=13; #could not be reliably determined as some values fell below the lower level of quantification; ‡determined after 
administration of evening dose.
Abbreviations: AUC(0–12), area under plasma concentration–time curve from time 0 to 12 hours after morning dose; AUC(0–24), area under plasma concentration–time curve 
from time 0 to 24 hours after morning dose; BID, twice daily; CV, coefficient of variation; FXa, factor Xa; G mean, geometric mean; LMWH, low-molecular-weight heparin; 
min, minimum; max, maximum; n, total number of subjects; ne, not estimated; peak, maximum observed plasma concentration; QD, once daily; sD, standard deviation; T1/2, 
half-life; Tpeak, observed time of peak anti-FXa activity; trough, minimum observed plasma concentration.  
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in VTEp patients, the Cmax value is somewhat lower and the Cmin 
value is slightly higher than that observed in our study,5 with a 
resulting Cmax/Cmin ratio of ∼7. For apixaban, the Cmax value in 
VTEp patients is similar to that in our study, but the Cmin value 
is higher,6 resulting in a Cmax/Cmin ratio of ∼1.5. Although the 
fluctuation values are lower, the difference between the two 
drugs is similar to that observed in healthy subjects.
Given that direct linear relationships between plasma 
concentration and AXA were evident for both apixaban and 
rivaroxaban, AXA findings are largely consistent with the PK 
of these agents. Peak AXA was observed at 2 hours postdose, 
coinciding with the Cmax for the respective compound, and 
apixaban maintained a lower AXA peak-to-trough ratio over the 
dosing interval. The difference between apixaban 2.5 mg BID 
and rivaroxaban 10 mg QD total daily AXA (AXA AUC(0–24)) 
was somewhat greater than the difference observed for expo-
sure, with AXA AUC(0–24) being ~34% higher for rivaroxaban. 
This finding is consistent with the difference observed in the 
slope of the AXA concentration regression lines for rivaroxa-
ban and apixaban. Although the regression for rivaroxaban 
was determined over a wider range of concentrations than that 
for apixaban, this is unlikely to provide an explanation for the 
difference in slope. Rivaroxaban has also been shown to have 
a greater effect than apixaban in the prothrombin time assay, 
at a concentration of 1,000 ng/mL, that cannot be attributed to 
the ∼5% difference in molecular weight.9
Despite a slightly lower daily AXA(0–24), apixaban 
AXA activity persisted well beyond the time at which the 
next scheduled BID dose was to be administered, whereas 
rivaroxaban AXA was near or below the lower limit of 
detection of the assay at the time of the next scheduled 
QD dose. Although QD administration may be favored 
based on convenience, it clearly results in higher peaks 
and lower troughs.12,15 The impact of greater fluctuation 
in levels of anticoagulation on clinical outcomes with oral 
FXa inhibitors is not known. Thus, the clinical importance 
of differences in rivaroxaban and apixaban AXA observed 
over their respective dosing intervals in this study remains 
to be determined.
The safety and efficacy of apixaban and rivaroxaban 
dosed QD and BID have been studied in Phase II clinical 
trials of VTE prevention. A Phase II dose-ranging clinical 
trial in patients undergoing total knee replacement was con-
ducted to evaluate the efficacy and safety of apixaban total 
daily doses of 5, 10, and 20 mg administered in QD and 
BID regimens.16 Numerically lower rates of VTE and death 
were observed with the apixaban 2.5-, 5-, and 10-mg BID 
regimens compared with the same total daily doses admin-
istered QD, whereas bleeding was similar for both BID and 
QD administration. A pharmacometric analysis performed 
with the apixaban Phase II VTE prevention data further 
supported a trend for a more favorable risk–benefit profile 
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Notes: Apixaban concentration, rivaroxaban concentration, and anti-FXa activity less than the lower limit of quantification at predose were set as 0. Apixaban concentration, 
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for the apixaban BID regimen.15 Thus, a BID regimen was 
selected for further study.
QD and BID regimens of rivaroxaban were evaluated 
in four separate Phase II studies of VTE prevention.17–20 No 
clear dose–response relationship was seen for efficacy across 
these trials, whereas bleeding increased with increasing 
doses. Comparisons of rivaroxaban QD and BID regimens 
have mainly focused on cross-study assessments, with the 
exception of one study20 that included a single QD regimen 
among several BID regimens. Overall, the safety and efficacy 
profiles of the rivaroxaban QD and BID regimens appeared 
to be similar,20 and a QD regimen was chosen for further 
study. While the outcomes of the Phase III clinical trials in 
VTE prevention have been favorable for both apixaban and 
rivaroxaban relative to low-molecular-weight heparin,21–27 
no comparisons of dosing frequency were performed in 
these trials.
This study was performed in a small number of 
healthy subjects receiving apixaban or rivaroxaban under 
supervision. As already mentioned, PK/PD differences in 
specific patient populations may alter the risk–benefit pro-
files of these agents in real-world clinical use. Additionally, 
factors such as compliance may impact outcomes, especially 
over the longer-term outpatient settings where dosing cannot 
be monitored. While compliance can be affected by dosing 
regimen, it can also be affected by the side-effect profile of 
the drug in question, as well as other factors. The compliance 
of both agents during real-world clinical use and its impact 
on clinical outcomes remains to be determined.
In summary, this study reports the first head-to-head 
comparison of apixaban and rivaroxaban PK and PD. 
Apixaban 2.5 mg BID demonstrated lower fluctuations in 
peak-to-trough plasma concentration and AXA throughout 
the dosing interval, lower interindividual variability in 
concentration and AXA, and a lower AXA AUC compared 
with rivaroxaban 10 mg QD. Although this study provides 
an informative comparison of apixaban and rivaroxaban PK 
and PD at dose regimens used for the prevention of VTE, 
it is important to note that it is difficult to extrapolate data 
from this healthy subject study to patients. It is possible that 
other factors encountered in clinical practice, such as drug 
interactions, varying degrees of renal function, and other 
patient characteristics may influence both the relative PK 
and PD profiles observed in this study and their relationships 
with real-world efficacy and safety outcomes. Although 
efficacy and safety exposure–response relationships in the 
prevention of VTE have been reported for apixaban, using 
AUC as the measure of exposure,15 these relationships have 
not been reported for rivaroxaban. Therefore, the impact of 
greater or lesser fluctuation in plasma concentration or AXA 
resulting from their respective dosing regimens on the relative 
efficacy and safety profiles of apixaban and rivaroxaban in 
clinical practice remains to be determined.
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